Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Pharmaceuticals Industry
Nov 21, 2008 04:22 PM
- China Medical Develops Predictor for Biologic Cancer Drug Success
Nov 20, 2008 02:38 PM
- You Don’t Have To Go To Tunisia To Find Solid Stocks… They’re Right Here In The U.S.
Nov 18, 2008 06:39 PM
- Oberweis: Small Cap Favorites
Nov 18, 2008 01:10 PM
- Five Healthcare Stocks To Diversify Your Portfolio
Nov 18, 2008 10:19 AM
- SFDA Approves China Medical’s HER2 FISH Probe
Nov 12, 2008 12:42 PM
- Who Will Replace GM In The Dow?
Nov 11, 2008 10:24 AM
- The Bear’s Case For Genentech
Nov 07, 2008 11:42 AM
- Short Ideas For Wednesday
Nov 05, 2008 10:50 AM
- Roche Expanding In Shanghai; Opens Partnership Office
Nov 04, 2008 01:46 PM
- NeMiss Retailers Expect Plenty of Shopping, Despite Slowdown
Nov 19, 2008 01:04 PM
- BRIEF: Former Inmate Sues Over Wrongful Rape Conviction
Nov 18, 2008 05:54 PM
- Man Linked By DNA Admits Killing Teacher in West County Center Lot
Nov 18, 2008 05:53 AM
- Suspect Pleads Guilty in 2000 Mall Parking Lot Murder of Webster Groves Teacher
Nov 17, 2008 09:52 PM
- Charlotte's DNA Backlog Slows Effort to Solve Crimes
Nov 16, 2008 12:59 PM
- Handling of Davie Police Officer's Criminal Sex Case Questioned: Did Davie Officer Get Special Treatment After Crime Reported?
Nov 16, 2008 03:54 AM
- Trials Leave Dent in Franklin County's Budget
Nov 10, 2008 11:53 AM
- Economists Say Indiana's Economic Pain Will Last Awhile
Nov 07, 2008 12:58 PM
- Bank Robber Apologizes to Victims
Nov 06, 2008 10:51 AM
- Election to benefit some industries, harm others
Nov 02, 2008 09:57 AM
- MattsonJack Study Reveals Cachexia Emerging As a Lucrative Opportunity for Pharma Companies
Nov 20, 2008 11:03 AM
- Genentech Issues Dear Healthcare Provider Letter Regarding a
2nd Case of PML in a Raptiva Patient
Nov 17, 2008 05:30 PM
- Best Practice Database Shares Best Practices in Biopharma Public Relations
Nov 13, 2008 04:00 PM
- Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
Nov 07, 2008 01:31 AM
- Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Nov 03, 2008 09:17 AM
- Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
Oct 27, 2008 09:21 AM
- Reminder - Register Your Company Now for the 2009 IR Global Rankings
Oct 24, 2008 12:53 PM
- Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Oct 20, 2008 01:00 AM
- Zacks Analyst Blog Highlights: Genentech, Inc., KeyCorp, Fifth Third Bancorp., Comerica Inc. And Altera Corp.
Oct 17, 2008 07:16 AM
- Seven Summits Research Releases Alerts on CHK, V, DNA, UPS, and TOL
Oct 16, 2008 09:31 AM
- Form 4 Yang Patrick Y For: Jul 21 (10K)
Jul 23, 2008 02:38 PM
- Form 4 LEVINSON ARTHUR D For: Jul 18 (10K)
Jul 22, 2008 01:36 PM
- Form 4 JUELSGAARD STEPHEN G For: Jul 18 (10K)
Jul 22, 2008 01:32 PM
- Form 4 GENENTECH INC For: Jul 16 Filed by: JUELSGAARD STEPHEN G (10K)
Jul 18, 2008 04:39 PM
- Form 4 GENENTECH INC For: Jul 16 Filed by: CLARK IAN T (10K)
Jul 18, 2008 04:22 PM
- Form 4 GENENTECH INC For: Jul 16 Filed by: DESMOND HELLMANN SUSAN D (10K)
Jul 18, 2008 12:37 PM
- Form 4 GENENTECH INC For: Jul 16 Filed by: SCHELLER RICHARD H (10K)
Jul 18, 2008 12:36 PM
- Form 4 GENENTECH INC For: Jul 16 Filed by: Tessier-Lavigne Marc (10K)
Jul 18, 2008 12:35 PM
- Form 3 GENENTECH INC For: Jun 04 Filed by: Tessier-Lavigne Marc (10K)
Jun 13, 2008 04:42 PM
- Form 4 GENENTECH INC For: Jun 06 Filed by: SCHELLER RICHARD H (10K)
Jun 10, 2008 02:18 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
DNA
|
Compare to S&P
|
| YTD |
16.40 %
|
104.54 %
|
| 4 Weeks |
-5.43 %
|
5.15 %
|
| 12 Weeks |
-20.25 %
|
26.72 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -1.33 %
|
|
EPS Growth in Last Year: 10.45 %
|
|
Sales Growth in Last Quarter: 5.44 %
|
|
Sales Growth in Last Quarter: 17.33 %
|
|
|
